Sunday , November 28 2021

[바이오 유망기업]⑨ Utrek keeps the global leading company for the next generation of immunocarcinogens



[ad_1]

[이데일리 이미나 기자]
[이데일리 김지섭 기자] "Innovative drug-based immunotherapeutic technologies will develop the therapy of cell therapy and antibody therapy and become a global leader in the field of immunosuppressive drugs through rapid commercialization."

Kwon Biung, a communal company spokeswoman, met with reporters at the Plaza Hotel in Jung-gu, Seoul, on September 16th.

Utrek is a biotechnology company that develops drugs for incompetent diseases such as cancer by immunotherapy using the 'immune system' which protects viruses and toxins in the human body. The mission statement "Utreks" also showed its intention to develop new immunotherapeutic drugs such as "EU" (new), "TI" (immunological therapy) and "LEX" (method).

The immunotoxicant treats cancer cells with a normal immune system or enhances the weakened immune system in various ways to remove cancer cells. Compared to conventional anti-cancer medicines or targeted cancer drugs that attack specific cancer cells, they are less drug-resistant and safe than adverse effects such as leukopenia and hair loss. According to GBI Research, the market for immunotherapy drugs is expected to grow at an average annual rate of 23.9% from 18 trillion won in 2015 to 86 billion won in 2022.

◇ Immunological research "Hanvoo" … Genuine original technology for immunotherapy

Kwon Biung-seh, who founded community services in February 2015, is the authority in the field of immunology, which works on the sale of Kangoo products. He was a professor of chemistry and bioscience at Ulsan University and Head of the Department of Immunocytochemistry at the National Center for Cancer at the University of Iale. Kwon said: "A study of immunology over the past 40 years led to the development of differentiated immunotherapy."

In particular, it was first observed in 1989 when it detected the 4-1BB receptor, which stimulated the "T cells" associated with the immuno-modulating drug of the antibody. T cells, immune cells, attack and destroy cancer cells. 4-1BB can selectively activate or reduce the immune function to activate T cells. Utrek uses this for the separation and cultivation of T cells from the blood in cancer patients, and then injects them into the body of the patient.

(EBViNT cell), which treats lymphoma, laryngeal cancer, gastric cancer, etc., is a single-phase glioblastoma / malignant tumor that treats ½ phase, non-human lung carcinoma and breast cancer. VTiNT cell, which treats glioma, etc., It is found in the first stage. "Aptiti Cell will end the second phase of clinical trials by 2020," he said. "Its goal is to approve it in 2022 by the US Food and Drug Administration (FDA) through the label of innovative drugs."

In addition, T-cell cancer treatment, which increases the effect of anti-cancer by the introduction of a gene that successfully detects and destroys cancer cells in T cells (CAR) The existing CAR-T agent carcinoma has caused side effects such as cytokine syndrome that non-selectively attacks zero cells and causes hypotension and acute kidney damage. However, CAR-T utility services have reduced the harmful effects by attacking only malignant cells, targeting the HDL-DR, an antigen that is expressed when normal cells change into malignant cells. Standardization of the production process and product standardization significantly reduced the cost of drugs, which reached several hundred million won. Other drugs such as EU101 and EU102, who are active in the treatment of cancer cells by activating the immune response of T cells, are developing.

These new developmental drugs are also actively seeking technological exports. Kwon said: "There are many technologies we have now, but it's impossible to develop everything." He said: "We will raise clinical costs through technology exports and cooperate with global pharmaceutical companies to build successful stories."

◇ New drug development in the United States, such as the bridge … & # 39; Global Big Pharma & # 39; aspiration

The main priority of Kvon is the establishment of a bridge in USA and Europe for the development of new drugs. In September, we signed a Memorandum of Understanding (MOU) with US JGBLI (JG Business Link International) and ABB Anti-Cell for successful entry into the United States. JGBLI will support research and development centers (R & D) in the United States and consult the College of Pharmaci in Mariland for the approval of cancer drugs. "This is the first step in clinical trials for T-cell therapy in the United States," said Kwon. "We will continue to strive to license immunocompromised drugs, starting with the VientiCell application".

KOSDAK's performance for clinical funding is also ahead of us. On December 15, Korea's preliminary projection was confirmed and confirmed the planned amount of 27.6 billion won to 36.4 billion won. He said: "The goal of the listing is to make the management transparent and to contribute to the growth of the company," he said. "From 2022 to the beginning of production and export of technology, etc. Growth since 2013, global anti-" We will achieve our vision. "

[ad_2]
Source link